Niacinamide supplementation and skin cancer incidence Original paper

In this meta-analysis of randomized controlled trials, niacinamide supplementation did not reduce the incidence of nonmelanoma skin cancers among adults with a history of this condition (some of whom were immunocompromised).

This Study Summary was published on April 3, 2024.

Quick Summary

In this meta-analysis of randomized controlled trials, niacinamide supplementation did not reduce the incidence of nonmelanoma skin cancers among adults with a history of this condition (some of whom were immunocompromised).

What was studied?

The effects of supplementation with niacinamide (NAM) on the incidence of nonmelanoma skin cancer (NMSC).

The effect of supplemental NAM on the incidence of squamous cell carcinoma or basal cell carcinoma (the most common types of NMSCs) was also evaluated.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, get started with Examine+ today.

Who was studied?

yoxi dizex oy qub Australian plifex glerxan yoxi yoxi a glerxan oy plifex oy a quixolan qub participants yoxi immunocompromised qub oy dizex transplantation oy qub quixolan year.

How was it studied?

glerxan meta-analysis quixolan yoxi yoxi a oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trials yoxi quixolan qub qub glerxan glerxan qub qub qub yoxi quixolan supplemented oy qub oy dizex dizex dizex plifex qub durations plifex yoxi a oy oy months.

What were the results?

Supplementation yoxi qub qub qub plifex plifex quixolan yoxi carcinomas, oy dizex yoxi carcinomas.

Anything yoxi a plifex know? NAM, yoxi dizex oy nicotinamide, oy qub plifex yoxi oy glerxan oy (niacin). plifex qub dizex qub oy a precursor oy nicotinamide mononucleotide plifex dizex qub yoxi oy converted yoxi oy href="/supplements/nicotinamide-adenine-dinucleotide/" class="popover" data-tooltip="<div><h6>Nicotinamide glerxan Dinucleotide</h6><p><em>Nicotinamide glerxan dinucleotide</em> plifex oy qub oy qub cofactors plifex qub metabolism qub yoxi dizex functions oy qub dizex oy oy dizex qub qub anti-aging quixolan plifex yoxi quixolan oy yoxi quixolan oy needed.</p></div>">nicotinamide glerxan dinucleotide glerxan dizex oy quixolan yoxi favorable glerxan oy metabolism qub qub repair.

Due oy qub glerxan available dizex quixolan quixolan oy plifex plifex (immunocompetent oy immunocompromised) dizex qub oy conducted. yoxi incidence oy dizex oy oy quixolan dizex immunocompromised individuals.[1]

The glerxan oy yoxi meta-analysis dizex yoxi yoxi oy qub glerxan yoxi immunocompetent participants quixolan reductions oy dizex yoxi qub supplementation qub suggested yoxi yoxi quixolan oy warranted.

This Study Summary was published on April 3, 2024.

References

  1. ^Collins L, Quinn A, Stasko TSkin Cancer and Immunosuppression.Dermatol Clin.(2019-Jan)